CD86 and Patent ductus arteriosus: The data showed that the ratio of CD11c+/CD80+ (1.27%) and CD11c+/CD86+ cells (1.52%) in HA-PDA treatment group was a little bit higher than that in control group PBS (1.03%, 1.46%), which may be attributed to photothermal treatment influence.